Vancouver, British Columbia–(Newsfile Corp. – January 22, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTC Pink: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce its inclusion in the Horizon North American Psychedelic ETF, the first ever psychedelic ETF of its kind. The new ETF is expected to start trading January 26, 2021 under the symbol “PYSK” on the NEO exchange.
The Psychedelic ETF invests in North American publicly-listed companies focused on psychedelic medicines, providing diversified exposure to the psychedelics industry, and is designed to reflect the evolution of the industry in a timely fashion. The underlying index of the Psychedelic ETF is the North American Psychedelics Stock Index and measures performance of its constituent companies.
“We’re thrilled to have Entheon included in Horizon’s Psychedelic ETF and look forward to supporting its development through our participation. The creation of this ETF and Index signals the growing acceptance of, and interest in, psychedelics as both a treatment and investment, and we’re proud to be a part of this growing community,” said Chief Executive Officer, Timothy Ko. “Our inclusion in this ETF also offers the practical advantage of providing Entheon with the potential for increased liquidity and awareness.”
About Entheon Biomedical Corp.
Entheon is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective N,N-dimethyltryptamine based psychedelic therapeutic products (“DMT Products“) for the purposes of treating addiction and substance use disorders. Subject to obtaining all requisite regulatory approvals and permits, Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics and licensed psychiatrists in the United States, certain countries in the European Union and throughout Canada.
About Horizon’s Psychedelic ETF & North American Psychedelic Index
At present, Horizon is the fourth largest ETF provider in Canada, and in 2017 established the first cannabis industry ETF. The underlying index of the Psychedelic ETF is the North American Psychedelic Stock Index, provided by German-based index provider Solactive. The Index is passive, weighing constituent companies according to their market cap.
On Behalf of the Board of Directors,
“Timothy Ko”
Timothy Ko, CEO
For more information, please contact the Company at:
Entheon Biomedical Corp.
Joseph Cullen, Investor Relations
Telephone: +1 (778) 919-8615
Joe@entheonbiomedical.com
https://entheonbiomedical.com/
For media inquiries, please contact Crystal Quast at:
Bullseye Corporate
Crystal Quast
Telephone: +1 (647) 529-6364
Quast@BullseyeCorporate.com
Cautionary Note on Forward-Looking Information
This news release contains forward‐looking statements and forward‐looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward‐looking statements or information. More particularly and without limitation, this news release contains forward‐looking statements and information relating to the Company’s inclusion in Horizon ETFs North American Psychedelic Index, the commencement date of trading of the Horizon’s ETF and other matters. The forward‐looking statements and information are based on certain key expectations and assumptions made by management of the Company. Although management of the Company believes that the expectations and assumptions on which such forward-looking statements and information are based are reasonable, undue reliance should not be placed on the forward‐looking statements and information since no assurance can be given that they will prove to be correct.
Forward-looking statements and information are provided for the purpose of providing information about the current expectations and plans of management of the Company relating to the future. Readers are cautioned that reliance on such statements and information may not be appropriate for other purposes, such as making investment decisions. Since forward‐looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to, the Company’s ability to raise further capital and the Company’s ability to obtain regulatory and exchange approvals. Accordingly, readers should not place undue reliance on the forward‐looking statements and information contained in this news release. Readers are cautioned that the foregoing list of factors is not exhaustive. The forward‐looking statements and information contained in this news release are made as of the date hereof and no undertaking is given to update publicly or revise any forward‐looking statements or information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws. The forward-looking statements or information contained in this news release are expressly qualified by this cautionary statement.
Neither the CSE nor the Investment Industry Regulatory Organization of Canada accepts responsibility for the adequacy or accuracy of this release.